Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
11/2003
11/27/2003US20030220268 New phenylalanine derivatives
11/27/2003US20030220256 Truncated 24kDa basic fibroblast growth factor
11/27/2003US20030220255 GLP-1 agonist and cardiovascular complications
11/27/2003US20030220248 Use of MP52 or MP121 for the treatment and prevention of diseases of the nervous system
11/27/2003US20030220243 A 37 amino acid peptide that is secreted by the L-cells of the intestine in response to food ingestion, because of their ability to stimulate insulin secretion, can be used for the treatment of diabetes, obesity and releated conditions
11/27/2003US20030220228 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
11/27/2003US20030219898 Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
11/27/2003US20030219875 Albumin fusion proteins
11/27/2003US20030219874 Comprises endothelial differentiation gene receptor proteins (EDG8) for monitoring receptivity to and/or diagnosing cancer, angiogenesis and inflammation
11/27/2003US20030219864 Novel variants of RANKL protein
11/27/2003US20030219496 Methods of treating vascular disease
11/27/2003US20030219495 To prevent or reverse hypotension, unstable angina, myocardial infarction or shock caused by the concomitant ingestion of a phosphodiesterase inhibitor such as sildenafil citrate and a NO-donor such as L-arginine or an organic nitrate
11/27/2003US20030219439 Genetic enginieered mixtures of complementary determining regions(CDR) antigens used for analyzing neutralizing epitopes and for prophylaxis of allergies and respiratory system disorders
11/27/2003US20030219438 Human antibodies that bind human TNFalpha
11/27/2003US20030219437 Administering antibodies used as antagonists to CD antigen ligands on the cells, for prophylaxis of cardiovascular, gastrointestinal or urogenital disorders
11/27/2003US20030219401 Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
11/27/2003US20030219375 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/27/2003CA2794297A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of amyloidosis
11/27/2003CA2794060A1 Methods and compositions using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of multiple myeloma
11/27/2003CA2752140A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
11/27/2003CA2752127A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of hepatocellular carcinoma
11/27/2003CA2752124A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
11/27/2003CA2752122A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of ovarian cancer
11/27/2003CA2727830A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma
11/27/2003CA2727824A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of solid tumors
11/27/2003CA2497601A1 Pyrroloquinoline quinone for treatment of cardiac injury and methods of use thereof
11/27/2003CA2486764A1 Tetrahydroisoquinoline derivatives
11/27/2003CA2486468A1 Improvements in delivery technology
11/27/2003CA2486302A1 Methods for the prevention and/or the treatment of neurological disorders
11/27/2003CA2486157A1 Opioid and opioid-like compounds and uses thereof
11/27/2003CA2486141A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
11/27/2003CA2486121A1 Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
11/27/2003CA2486106A1 Compounds and methods for inhibiting selectin-mediated function
11/27/2003CA2486061A1 Using a selective inos inhibitor for the treatment of respiratory diseases and conditions
11/27/2003CA2485081A1 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
11/27/2003CA2484646A1 Hormone replacement therapy using a combination of conjugated estrogens and trimegestone
11/27/2003CA2484631A1 Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles
11/27/2003CA2484233A1 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
11/27/2003CA2483770A1 Trimegestone and estrogens for treating post menopausal disorders
11/27/2003CA2482756A1 Indole derivatives and the use thereof as cb<sb>2</sb> receptor ligands
11/27/2003CA2482348A1 Combinations of an ace inhibitor, a calcium channel blocker and a diuretic
11/26/2003EP1365246A1 Diagnostics and therapeutics for diseases associated with neuromedin U2 receptor (NMU2)
11/26/2003EP1365024A1 Traf3-binding b cell-specific receptor
11/26/2003EP1365022A1 Adiponectin-associated protein
11/26/2003EP1364958A1 Glycopyranosyloxypyrazole derivatives and medicinal use thereof
11/26/2003EP1364957A1 Glycopyranosyloxypyrazole derivatives and medicinal use thereof
11/26/2003EP1364953A1 Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension
11/26/2003EP1364952A1 Bicyclic nitrogenous fused-ring compound
11/26/2003EP1364950A1 Pyridopyrimidine or naphthyridine derivative
11/26/2003EP1364949A1 Jnk inhibitor
11/26/2003EP1364943A1 Novel cystine derivatives and inhibitors for the activation of inflammatory factors
11/26/2003EP1364660A1 Drug-releasing system of biodegradable polymer type
11/26/2003EP1364653A1 Casoase 3 inhibitors
11/26/2003EP1364647A1 Hypoglycemic agent
11/26/2003EP1364628A1 Coated medical devices
11/26/2003EP1364069A1 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
11/26/2003EP1364023A2 Method of diagnosing and treating cartilage disorders
11/26/2003EP1364019A2 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
11/26/2003EP1364014A2 Novx proteins and nucleic acids encoding same. diagnostic and therapeutic uses
11/26/2003EP1364002A2 Process for the preparation of neutrophil inhibitory factor
11/26/2003EP1363993A2 METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK)
11/26/2003EP1363944A2 High-affinity antagonists of elr-cxc chemokines
11/26/2003EP1363914A1 Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents
11/26/2003EP1363913A2 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
11/26/2003EP1363910A2 Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
11/26/2003EP1363906A2 Heterocyclic inhibitors of erk2 and uses thereof
11/26/2003EP1363904A1 Pyrazoles as tgf inhibitors
11/26/2003EP1363903A1 Indole derivatives and their use as gnrh antagonists
11/26/2003EP1363902A1 Chemical compounds
11/26/2003EP1363900A1 Isoindole-imide compounds as tnf-inhibitors
11/26/2003EP1363898A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/26/2003EP1363897A2 Antagonists of mcp-1 function and methods of use thereof
11/26/2003EP1363891A2 Anthrone derivatives and their use as jnk inhibitors
11/26/2003EP1363879A2 Sulfide and disulfide compounds and compositions for cholesterol management and related uses
11/26/2003EP1363876A1 Glucocorticoid receptor modulators
11/26/2003EP1363874A2 Tryptase inhibitors
11/26/2003EP1363668A2 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
11/26/2003EP1363657A2 Method for promoting neovascularization using a tweak agonist and an angiogenic factor
11/26/2003EP1363656A2 Tripeptides and tripeptide derivatives for the treatment of postlesional diseases of the nervous system
11/26/2003EP1363653A2 Methods and compositions for enhancing angiogenesis
11/26/2003EP1363651A1 Herbal compositions useful as chemopreventive and therapeutic agents
11/26/2003EP1363648A1 Agastache rugosa extract and composition containing tilianin isolated and purified from said extract having anti-inflammatory activity and anti-atherogenic activity
11/26/2003EP1363643A2 Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
11/26/2003EP1363640A2 Nucleic acid derivatives
11/26/2003EP1363636A1 A method for the treatment of heart failure
11/26/2003EP1363635A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
11/26/2003EP1363632A1 Receptor selective cannabimimetic aminoalkylindoles
11/26/2003EP1363631A2 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/26/2003EP1363629A1 Kappa opioid receptor ligands
11/26/2003EP1363622A1 Pharmaceutical compositions including sampatrilat dispersed in a lipoidic vehicle
11/26/2003EP1363621A1 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
11/26/2003EP1363619A2 Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
11/26/2003EP1363610A2 Carotenoids as anti-hypertension agents
11/26/2003EP1363609A2 An anti-atherosclerosis composition containing carotenoids and method for inhibiting ldl oxidation
11/26/2003EP1363606A1 Use of gaba[a] inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators or vitamin e for the treatment of coginitive disorders
11/26/2003EP1363605A1 Gaba-receptor modulators for the treatment of neurodegenerative diseases of the eye
11/26/2003EP1363528A2 Methods for diagnosing and treating heart disease
11/26/2003EP1363508A1 Emulsions and aqueous dispersions of phytosterols
11/26/2003EP1268487B1 Tricyclic protein kinase inhibitors
11/26/2003EP1124541B1 Application of water-soluble or water-dispersible graft polymerizates which contain poly-ether and which are used as a coating agent, a binding agent and/or as a film-forming auxiliary agent in pharmaceutical forms of administration
1 ... 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 ... 1595